Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
121.40
-2.62 (-2.11%)
Nov 20, 2026, 4:00 PM EST - Market closed
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Protagonist Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $182.36. The average 1-year stock price forecast is 50.21% higher than the current stock price, while the lowest is $151 (+24.38%) and the highest is $225 (+85.34%).
Price Target: $182.36 (+50.21%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Protagonist Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 10 | 10 | 11 | 11 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Buy Maintains $190 | Buy | Maintains | $190 | +56.51% | Nov 10, 2026 |
| UBS | UBS | Buy Maintains $184 | Buy | Maintains | $184 | +51.57% | Nov 10, 2026 |
| Wedbush | Wedbush | Buy Maintains $173 | Buy | Maintains | $173 | +42.50% | Nov 10, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $149 → $151 | Buy | Reiterates | $149 → $151 | +24.38% | Nov 9, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $170 → $221 | Buy | Reiterates | $170 → $221 | +82.04% | Nov 6, 2026 |
Financial Forecast
Revenue This Year
565.18M
from 46.02M
Increased by 1,128.22%
Revenue Next Year
235.79M
from 565.18M
Decreased by -58.28%
EPS This Year
5.09
from -2.05
EPS Next Year
0.35
from 5.09
Decreased by -93.09%
EPS and Forward PE are based on non-GAAP adjusted numbers.